LAURA THOMSON: Open Payments
NPI 1710358650 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$890 in 38 payments from 10 companies in 2025. Trend: 2023 $17,097 · 2024 $4,051 · 2025 $890
Food & beverage: $707Education: $183
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $353 |
| Teva Pharmaceuticals USA, Inc. | 4 | $215 |
| Axsome Therapeutics, Inc. | 3 | $159 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| GlaxoSmithKline, LLC. | 1 | $32 |
| Alkermes, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: VRAYLAR, Auvelity, HETLIOZ, TRELEGY ELLIPTA, AUSTEDO XR, ARISTADA, XIFAXAN, Qelbree.
Industry payments across KY — which companies pay providers there.
